Keta-Care - Antidepressant and Anxiolytic Effects of Intranasal Ketamine Self-administration in Palliative Care Cancer Patients: an Open-label Feasibility Study
Phase: EARLY_PHASE1 | Sponsor: University of Zurich | Compound: Ketamine
- Status
- planned
- Institution
- University of Zurich
- Start date
- 2025-04-01
- End date
- 2026-12-01
- Registry ID
- NCT06665568
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.